-
Innovation Ranking
NewInnovation Ranking – CSL Ltd
CSL Ltd (CSL) discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-311 in Allergic Asthma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CSL-311 in Allergic Asthma Drug Details: CSL-311 is under development for the treatment of allergic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-112 in Acute Coronary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CSL-112 in Acute Coronary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CSL-112 in Acute Coronary Syndrome Drug Details: CSL-112 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-112 in Acute Coronary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CSL-112 in Acute Coronary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CSL-112 in Acute Coronary Syndrome Drug Details: CSL-112 is under development...
-
Company Insights
Innovation and Patenting activity of CSL Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CSL Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-787 in Bronchiectasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CSL-787 in Bronchiectasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CSL-787 in Bronchiectasis Drug Details: CSL-787 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-040 in Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CSL-040 in Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CSL-040 in Transplant Rejection Drug Details: CSL-040 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-346 in Diabetic Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CSL-346 in Diabetic Nephropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CSL-346 in Diabetic Nephropathy Drug Details:CSL-346 (VEGF-B antagonist) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-346 in Lipid Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CSL-346 in Lipid Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CSL-346 in Lipid Disorders Drug Details:CSL-346 (VEGF-B antagonist) is under development for the...
-
Sector Analysis
NewCell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...